Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 192 for “"Hydroxyurea"”.

  1. Tissue specific accumulation of hydroxyurea in elasmobranchs

    Hydroxyurea is an antibiotic and antiproliferative agent used clinically in the treatment of select cancers, sickle cell anemia, HIV, and myeloproliferative diseases. Hydroxyurea has never been detected in elasmobranch tissues and has only been detected in trace amounts in a single eukaryote. Using …

    guelph Repository record for Tissue specific accumulation of hydroxyurea in elasmobranchs (opens in a new tab)

  2. Defining a novel role of hydroxyurea on erythrocytes

    Thesis (Ph. D.)--Michigan State University. Chemistry, 2008

    msu Repository record for Defining a novel role of hydroxyurea on erythrocytes (opens in a new tab)

  3. Stroke Training, Research, and Education Toward Capacity With Hydroxyurea (Stretch)

    … identifies children at risk, and treatment with hydroxyurea. This study will inform how public health leaders can mitigate stroke risk among children with SCA in sub-Saharan Africa and how TCD screening fits into a larger context of providing safe, effective care. Methods: Stroke Training, …

    iupui Repository record for Stroke Training, Research, and Education Toward Capacity With Hydroxyurea (Stretch) (opens in a new tab)

  4. Pathways of Hydroxyurea Synthesis in the Mitochondria of the Little Skate (Leucoraja erincea)

    Hydroxyurea (HU) is an anti-proliferative and anti-microbial compound that is widely used in medical therapy but is also found to occur naturally in different phylogenetic groups. However, it is still unknown how this compound is endogenously synthesized. I hypothesized that HU is synthesized …

    guelph Repository record for Pathways of Hydroxyurea Synthesis in the Mitochondria of the Little Skate (Leucoraja erincea) (opens in a new tab)

  5. Barriers to hydroxyurea use in sickle cell disease: perspectives of providers, families, and adults

    … on morbidity, mortality, and quality of life. Hydroxyurea has been FDA approved since 1998 as a disease-modifying therapy for SCD. However, hydroxyurea has not been optimally utilized for those with SCD. The purpose of this study was to evaluate reasons for hydroxyurea use, from the …

    bu Repository record for Barriers to hydroxyurea use in sickle cell disease: perspectives of providers, families, and adults (opens in a new tab)

  6. A Meta-Analysis of Hydroxyurea Use for β-thalassemia: Implications for Clinical Practice and Medical Education

    … of the problems associated with current therapy. Hydroxyurea (HU), an oral chemotherapeutic drug, is expected to increase hemoglobin, thereby minimizing the burden of blood transfusion and its complications. The objective of this study was to conduct a systematic review and meta-analysis to …

    calgary Repository record for A Meta-Analysis of Hydroxyurea Use for β-thalassemia: Implications for Clinical Practice and Medical Education (opens in a new tab)

  7. Examining the Effect of Hydroxyurea Treatment on Acute Care Spending and Utilization among Patients with Sickle Cell Disease

    … often with particularly high emergency care use. Hydroxyurea (HU), an inexpensive therapeutic drug, has proven to be effective at reducing pain crises. However, HU is underutilized for a variety of reasons including lack of insurance coverage, misperceptions and negative beliefs, and lack of …

    washington Repository record for Examining the Effect of Hydroxyurea Treatment on Acute Care Spending and Utilization among Patients with Sickle Cell Disease (opens in a new tab)

  8. Predictors Of Use Of Hydroxyurea And Its Impact On Clinical And Economic Outcomes Among Children With Sickle Cell Disease

    … assess the prevalence and predictors of use of hydroxyurea (HU) and its impact on clinical and economic outcomes in pediatric patients with sickle cell disease (SCD) enrolled in Medicaid. Methods: A cohort of patients with SCD was identified in 2006 using ICD-9-CM codes from Medicaid claims from …

    mississippi Repository record for Predictors Of Use Of Hydroxyurea And Its Impact On Clinical And Economic Outcomes Among Children With Sickle Cell Disease (opens in a new tab)

  9. The effect of hydroxyurea treatment on DNA methylation and gene expression in essential thrombocythaemia and polycythaemia vera: a cross-species study

    … platelets leading to thrombosis and haemorrhage. Hydroxyurea (HU), is the first line treatment for high-risk PV and ET patients since it effectively reduces the haematocrit, platelets and white blood cells counts. Mechanistically, HU acts by inhibiting the ribonucleotide reductase enzyme, blocking …

    kings Repository record for The effect of hydroxyurea treatment on DNA methylation and gene expression in essential thrombocythaemia and polycythaemia vera: a cross-species study (opens in a new tab) Download PDF for The effect of hydroxyurea treatment on DNA methylation and gene expression in essential thrombocythaemia and polycythaemia vera: a cross-species study (opens in a new tab)

  10. Review of economic studies of sickle cell disease and adherence to hydroxyurea and clinical and economic outcomes among Texas Medicaid enrollees with sickle cell disease

    … economic burden of SCD in the U.S.; 2) assessed hydroxyurea medication adherence and its association with vaso-occlusive crisis (VOC)-related events and healthcare utilization and costs. The systematic review (N=21 articles) revealed mean total SCD healthcare costs (2019 USD) ranged from $19,464 …

    texas Repository record for Review of economic studies of sickle cell disease and adherence to hydroxyurea and clinical and economic outcomes among Texas Medicaid enrollees with sickle cell disease (opens in a new tab)

  11. Use of medications and services for the management of sickle cell disease

    … excessive costs. Preventative therapies, such as hydroxyurea, are known to prevent or reduce the frequency of SCD complications. The purpose of this study was to determine medication and healthcare services utilization for the management of SCD, in terms of index and subsequent therapies and …

    texas Repository record for Use of medications and services for the management of sickle cell disease (opens in a new tab)

  12. Analysis of essential thrombocythemia and its treatment

    … to lower the risk of a thrombotic event. Hydroxyurea and low-dose aspirin have been the gold-standard of treatment for ET patients. This thesis sought to compare the current available therapy with second-line treatments and investigational treatments. Anagrelide is a key second-line …

    bu Repository record for Analysis of essential thrombocythemia and its treatment (opens in a new tab)

  13. 5-azacytidine increases the activity of neomycin phosphotransferase II in transgenic Nicotiana tabacum : posttranslational mechanism might play an important role

    … not be blocked by the DNA replication inhibitor, hydroxyurea, nor by its analogue, cytidine. In addition, the level of mRNA of npt II was not increased by 5-azacytidine, indicating the effect of 5-azacytidine was not at the transcriptional level. Treatment with cycloheximide, a protein synthesis …

    utk-theses Repository record for 5-azacytidine increases the activity of neomycin phosphotransferase II in transgenic Nicotiana tabacum : posttranslational mechanism might play an important role (opens in a new tab)

Page 1 of 10